OCUMENSION-B (01477) announced that the Board of Directors considers it necessary to implement incentive measures to support the Group's strategic growth objectives and maintain a competitive advantage in talent recruitment and retention. To recognize the long-term dedication and valuable contributions of the grantees towards achieving the Group's research and development (R&D) and commercial milestones, the Board resolved on May 12, 2026, to grant 7,932,100 stock options, covering 7,932,100 shares, to 498 grantees (including Dr. Hu Zhaopeng, an executive director of the Company, and one senior management member) under the 2021 Share Option Scheme. Concurrently, 7,932,100 share awards, covering 7,932,100 shares, were granted to the same 498 grantees (including Dr. Hu and one senior management member) under the 2021 Share Award Scheme. These grants represent approximately 0.97% and 0.97%, respectively, of the Company's total issued and outstanding share capital (excluding treasury shares) as of the grant date.